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Abstract: The signal transducer and activator of transcription Stat5 is transiently activated 
by growth factor and cytokine signals in normal cells, but its persistent activation has been 
observed in a wide range of human tumors. Aberrant Stat5 activity was initially observed 
in leukemias, but subsequently also found in carcinomas. We investigated the importance 
of Stat5 in human tumor cell lines. shRNA mediated downregulation of Stat5 revealed the 
dependence of prostate and breast cancer cells on the expression of this transcription factor. 
We extended these inhibition studies and derived a  peptide aptamer (PA) ligand, which 
directly interacts with the DNA-binding domain of Stat5 in a yeast-two-hybrid screen. The 
Stat5 specific PA sequence is embedded in a thioredoxin (hTRX) scaffold protein. The 
resulting  recombinant  protein  S5-DBD-PA  was  expressed  in  bacteria,  purified  and 
introduced  into  tumor  cells  by  protein  transduction.  Alternatively,  S5-DBD-PA  was 
expressed in the tumor cells after infection with a S5-DBD-PA encoding gene transfer 
vector.  Both  strategies  impaired  the  DNA-binding  ability  of  Stat5,  suppressed  Stat5 
dependent transactivation and caused its intracellular degradation. Our experiments describe 
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a  peptide  based  inhibitor  of  Stat5  protein  activity  which  can  serve  as  a  lead  for  the 
development of a clinically useful compound for cancer treatment. 
Keywords: peptide aptamer (PA); signal transducer and activator of transcription 5 (Stat5); 
RNA  interference  (RNAi);  yeast-two-hybrid  (Y2H);  protein  transduction;  prostate  and 
breast cancer cell lines; inhibition of DNA-binding 
 
1. Introduction 
The  Jak-Stat  signaling  pathway  is  an  essential  cellular  communication  route  from  the  plasma 
membrane  to  the  nucleus.  It  can  be  activated  by  cytokines,  hormones  and  growth  factors  and  is 
involved in the regulation of homeostasis and tissue-specific functions [1,2]. In mammals the Stat 
protein family consists of seven members (Stat1, 2, 3, 4, 5a, 5b and 6) with similar domain structures 
and lengths ranging from 750 to 850 amino acids. They comprise an amino terminal tetramerization 
domain,  followed  by  a  coiled-coil  and  central  DNA-binding  domain  (DBD),  a  linker  domain,  
a characteristic SH2-domain and a carboxyl terminal transactivation domain. The TAD determines the 
tissue and cell type specific activity of Stats. Its function is modulated by secondary modifications and 
cofactor  interactions.  Activation  of  Stats  occurs  via  phosphorylation  of  a  tyrosine  residue  located 
between  the  SH2-  and  TAD-domains.  The  activating  kinases  comprise  receptor  associated  Janus 
family kinases (Jak), receptor tyrosine kinases, e.g., EGFR or cytoplasmic tyrosine kinases, e.g., Src. 
Stat proteins form transactivating dimers of parallel conformation by reciprocal interaction of their 
SH2 and their tyrosine phosphorylated domains [3]. This conformation exposes a nuclear localization 
signal  (NLS)  within  the  DBD  of  Stat  dimers  [4],  which  allows  them  to  bind  to  importin-α  and 
translocate into the nucleus. There they bind to consensus GAS-motifs, gamma interferon activated 
site: TTCNNNGAA, present in target gene promoters. Additional non-canonical functions, functions 
not  dependent  upon  the  transcriptional  transactivation  of  genes,  have  recently  been  described  for 
members of the Stat family. Phosphorylated dimers or non-phosphorylated monomers of Stat3 and 
Stat5 can assume additional functions in various subcellular compartments. These functions regulate the 
maintenance and modification of mitochondria, the Golgi apparatus and rough endoplasmatic reticulum, 
the modification of heterochromatin and the cytoskeleton as well as cofactor activities [1,5,6]. 
The  isoforms  Stat5a  and  Stat5b  share  95%  sequence  identity  at  the  protein  level.  Homo-  and 
heterodimer can be formed. They were originally identified as transcription factors of milk protein 
genes [7,8], but many additional Stat5-mediated functions have since been discovered. Both genes are 
ubiquitously expressed, and 3,000 to 100,000 molecules have been detected per cell, depending on the 
cell type and differentiation state [9,10]. Stat5 is a master regulator of hematopoiesis and mammogenesis 
and also exerts a strong impact on immune, prostate and liver cell functions. The activation of Stat5 is 
linked to malignant transformation in these tissues. The deregulation of the extent and the duration of 
Stat3 and Stat5 activation is an important contributor to tumorigenesis. Persistently activated Stat3 and 
Stat5 molecules and Stat induced target gene expression can be found in tumor cells. They can regulate 
hallmarks of cancer [11] and cause increased proliferation, survival, immune evasion, angiogenesis, 
migration and metastasis or reprogramming of energy metabolism [12,13]. The survival of tumor cells Pharmaceuticals 2013, 6  962 
 
 
can become dependent on the continuous activity of Stat3 or Stat5. Tumor cells react to their inhibition 
with induction of apoptosis. Both, Stat3 and Stat5, represent promising molecules in targeted cancer 
therapy. In hematological malignancies, the constitutive Stat5 activity, induced by leukemic oncogenes 
like Bcr-Abl, is associated with tumor maintenance by regulating survival, self-renewal and expansion 
of leukemic stem- and progenitor cells [14–16]. In solid tumors the deregulation of Stat5 can be a 
consequence of an excess of activating ligands in the tumor microenvironment, but also a consequence 
of the overexpression or mutation of cognate receptors. However, aberrant Stat5 activation does not 
equally affect the phenotypes of tumors of different origins. In prostate cancers, constitutive Stat5 
activity is associated with the development of aggressive, fast proliferating and invasive phenotypes. 
The  activity  of  Stat5  in  breast  cancers  is  correlated  with  more  differentiated  and  less  invasive 
phenotypes and a more favorable clinical outcome [17]. 
The transforming potential of persistently activated Stat5 is not limited to particular indications. We 
evaluated Stat5 expression and activity in solid tumor cells of different origins. Four human tumor cell 
lines,  derived  from  breast  (T-47D),  prostate  (PC-3),  epidermal  (A431)  and  colorectal  (HCT116) 
cancers, were employed and their response to the inhibition of Stat5 was investigated. Two approaches 
to  the  inhibition  of  Stat5  were  used.  RNA  interference  was  used  to  affect  the  stability  and  the 
translation of Stat5 specific mRNA and cause the downregulation of its expression. shRNAs directed 
against both isoforms of Stat5 were derived. The effects of Stat5 inhibition due to downregulation of 
mRNA were compared to the effects elicited by an inhibitor of the DNA-binding function of Stat5. 
This was achieved by a peptide aptamer (PA) ligand which specifically binds to the DBD of Stat5  
(S5-DBD-PA: Stat5-DNA-binding domain specific peptide aptamer). 
We  employed  a  peptide-based  ligand  of  Stat5  as  a  specific  inhibitor,  because  Stat5  lacks 
hydrophobic  binding  pockets,  which  usually  characterize conventional  drug  targets  and  which  are 
necessary to identify effective inhibitors of low molecular weight. Proteins often interact with each 
other  through  flat  surfaces  and  their  interaction  is  not  necessarily  dependent  on  a  presence  of 
hydrophobic pocket structures [18]. PA can therefore be exploited as specific ligands and potential 
inhibitors. They are  able to  bind to any  pre-determined target  domain and can be developed into 
therapeutic agents. They possibly can inhibit a broad spectrum of intracellular proteins and thus extend 
the range of conventional drug targets. Yeast-two-hybrid screens with synthetic and random 12mer 
peptides as prey constructs have been used to identify a PA sequence, which binds to the DNA-binding 
domain of Stat5 (Stat5-DBD) with high specificity and affinity. The PA sequence has been displayed 
in a constrained and unique conformation on the surface of a stable scaffold protein, by introduction in 
the protruding active site of a modified version of the human thioredoxin protein (hTRX). Additional 
functional domains were added which optimized the expression of the recombinant S5-DBD-PA protein 
construct, allowed for its purification and its delivery into target cells by protein transduction [19]. 
Complex formation of the Stat5-DBD with S5-DBD-PA led to the inhibition of the DNA binding 
capacity  of  Stat5,  prevented  nuclear  translocation  of  Stat5  dimers  and  induced  its  proteasomal 
degradation. The expression of Stat5-shRNA or S5-DBD-PA upon lentiviral gene transfer strongly 
affected tumor cell viability. The same was observed upon uptake of recombinant S5-DBD-PA protein 
added to the cell culture medium. HCT116 colorectal carcinoma cells served as controls, these cells 
express only very low levels of Stat5 and are not dependent on Stat5 functions. However, the cell lines 
A431 and T-47D also express relatively low levels of tyrosine phosphorylated Stat5. Nevertheless, Pharmaceuticals 2013, 6  963 
 
 
survival of these cells seems to be sensitive to Stat5 downregulation, an effect possibly due to the 
inhibition  of  the  non-transcriptional  functions  of  Stat5.  Therapeutic  agents  able  to  discriminate 
between  the  individual  functions  of  Stat5  in  different  subcellular  compartments  might  become 
desirable for effective tumor therapy and the prevention of side effects in normal tissues. 
2. Results and Discussion 
2.1. RNA Interference Validates Stat5 as a Therapeutic Target in Breast, Prostate and Epidermoid 
Carcinoma Cells 
Stat5  activation  has  been  shown  to  strongly  influence  the  growth  and  survival  of  leukemic  
cells [14,16,20]. Leukemia associated oncogenic kinases, e.g., Bcr-Abl, Flt3-ITD, c-kit(D816V) or 
Jak2(V617F) are able to phosphorylate Stat5 and contribute to its persistent activation [15,21–23]. 
Aberrant  Stat5  activity  has  also  been  observed  in  solid  tumors.  Activation  occurs  mainly  as  a 
consequence of mutations or overexpression of cytokine receptors and para- and autocrine signaling of 
secreted  ligands  present  in  the  tumor  microenvironment.  Stat5  activation  can  cause  induction  of 
aggressive tumor cell growth of prostate cancer cells or sustain a more differentiated and non-invasive 
phenotype in breast tumor cells [17,24]. 
We  investigated  tumor  cell  lines  derived  from  different  types  of  human  cancer  and  performed 
downregulation experiments with Stat5 specific shRNA. The sequences were chosen to affect both 
isoforms of human Stat5, Stat5a and Stat5b. Four tumor cell lines were selected. They vary with 
respect to Stat5 expression and activation under normal culture conditions. The prostate epithelial PC-3 
cell line, derived from bone marrow metastasis of a patient with grade IV prostate adenocarcinoma, 
exhibits the highest Stat5 tyrosine phosphorylation when compared to the other cells (Figure 1a). This 
aggressive  tumor  cell  line  is  characterized  by  a  deletion  of  the  Stat3  and  Stat5b  gene  locus  and 
exclusively expresses Stat5a [25]. It also carries an amplification of the c-myc gene and p53 and PTEN 
loss of function mutations [26]. Autocrine prolactin signals (Prl) are responsible for the constitutive 
activation  of  Stat5  in  these  cells,  which  is  further  enhanced  by  reduced  levels  of  SOCS  protein 
(suppressor  of  cytokine  signaling)  expression,  a  negative  regulator  of  Stat  signaling  [27,28].  
The  epidermal  carcinoma  cell  line  A431  shows  a  basal  level  of  Stat5  tyrosine  phosphorylation, 
although  much  lower than  PC-3  cells.  This cell line is  characterized by an  overexpression of the 
prolactin  (PrlR)  and  epidermal  growth  factor  receptor  ErbB1.  Additionally,  the  formation  of  
self-activating ErbB2/ErbB4 heterodimers can be detected. Stat proteins, including Stat5, can be found 
associated with overexpressed ErbB receptors in melanoma and epidermoid carcinoma like the A431 
cell line. This association is accompanied by an increased phosphorylation of Stat proteins by the 
intrinsic ErbB-receptor kinase activity or by recruited Src family kinases [29]. In both cell lines, the 
downregulation of Stat5 expression by lentiviral transfer of Stat5 directed shRNA, resulted in a strong 
decrease of cell growth and viability (Figure 1a,b). In the PC-3 cell line, this dependency can possibly 
be  explained  to the  loss  of  expression  of  anti-apoptotic  and  growth promoting  genes, induced  by 
constitutive Stat5a activation. In these cells, it cannot be compensated by Stat3 due the deletion of this 
gene. In many prostate cancers the transcriptional activity of Stat5 is enhanced by a synergism of Pharmaceuticals 2013, 6  964 
 
 
active Stat5-dimers with the androgen receptor [30]. Similar effects of Stat5 inhibition by RNAi or 
antisense oligonucleotides have been observed before [31,32]. 
Figure 1. Infection with a lentivirus gene transfer vector encoding Stat5-directed shRNA 
reduces Stat5 expression and suppresses the growth and viability of human tumor cells.  
(a) A431 epidermal and PC-3 prostate carcinoma cell lines were infected with lentiviruses 
encoding  either  the  empty  vector  (LeGO-G:  eGFP),  a  scrambled  shRNA  (LeGO-C: 
mCherry)  or  pairs  of  shRNA  specific  for  the  mRNA  of  the  human  Stat5a  and  Stat5b 
isoforms.6 days after infection knockdown-efficiency was verified by western blot, using 
antibodies recognizing either total or tyrosine phosphorylated Stat5 protein. The detection 
of total Stat3 served as a control of shRNA specificity. Eight days after infection cell 
density and morphology was documented by phase contrast and fluorescence microscopy. 
(b) Over a period of 20 days after viral transduction changes in proliferation and viability 
of A431 and PC-3 cells were measured by XTT assay at regular intervals. The infection 
with empty vector and Stat5-shRNA expressing lentiviruses was done in triplicates and the 
simultaneous  infection  with  scrambled  shRNA  expressing  lentiviruses  was  done  once. 
Results are shown as the percentage of viable cells compared to the mock-treated control.  
(c) The same experiments were performed with the T-47D breast and HCT116 colorectal 
cancer cell line. (n = 3; Ø ±  SD) Significantly reduced XTT-values in comparison to empty 
vector expressing cells are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001 (2-way-ANOVA 
with Bonferroni correction). 
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The relatively low levels of Stat5 tyrosine phosphorylation in A431 cells suggest that the effects 
observed upon Stat5 downregulation might be due to Stat5 functions independent from transcriptional 
induction. In phenotypically related melanoma cells, correlations between the loss of Stat5-mediated 
expression of the anti-apoptotic genes Bcl-2 or Bcl-xL and enhanced cell death have been observed [33,34]. 
The delivery of Stat5-shRNA into T-47D breast cancer cells led to a similar conclusion. This cell line 
has been derived from an invasive adenocarcinoma of the mammary ductal epithelium. It exhibits 
overexpression of PrlR and the estrogen receptor (ER), but no activated Stat5 was detected under 
normal cell culture conditions. In spite of the absence of activated Stat5, downregulation of Stat5 by 
RNAi also resulted in a strong decrease of cellular growth and viability. This indicates a Stat5 dependence 
of these cells unrelated to its transactivation function (Figure 1c). T-47D cells have been used as a 
model system to study mechanisms of Stat5-regulated phenotypes. Thereby effects of Stat5 inhibition 
were analyzed in the context of Prl stimulation. The strong growth suppression, however, induced by 
the downregulation of Stat5a and Stat5b mRNA utilization, has not been observed before [35–37].  
The growth inhibition is most likely due to effects resulting from Stat5 downregulation. Cytotoxic 
effects, caused by an excessive shRNA expression and an oversaturation and exhaustion of the shRNA 
processing machinery [38] can most likely be excluded. Infection of the cells with viruses encoding an 
irrelevant shRNA sequence had no influence on the viability of the cells. Since there is little or no 
Stat5-regulated gene expression in unstimulated T-47D cells, these observations suggest an influence 
of non-phosphorylated Stat5 on the maintenance of cellular survival. 
Recent  studies  identified  non-canonical  activities  of  non-phosphorylated  Stat5  involved  in  
the  formation  of  the  heterochromatin  structure  and  the  function  of  cell  organelles  [6,39–41].  
Non-phosphorylated  Stat5  monomers  are  permanently  associated  with  the  Golgi  apparatus  in 
endothelial and smooth muscle cells. Downregulation of Stat5a and Stat5b resulted in the dilatation 
and fragmentation of Golgi cisternae, a tubule-to-cyst change in the ER, the distortion of the nucleus 
and  reduced  mitochondrial  function.  The  cells  showed  a  cytoskeletal  deformation  and  a  round 
morphology,  comparable  to  the  observations  we  made  with  A431  and  PC-3  cells  (Figure  1a).  
In contrast, HCT116 colorectal carcinoma cells, characterized by a very low Stat5 expression, survive 
Stat5  downregulation.  The  viability  of  these  cells  was  only  slightly  influenced  by  the  lentiviral 
transduction of Stat5-shRNA (Figure 1c). Other Stat family members could possibly compensate for 
the  Stat5  functions.  Nevertheless,  the  morphology  of  HCT116  cells  seemed  also  slightly  to  be 
influenced by Stat5 downregulation. This is reminiscent of recent observations made by conditional 
Stat5 knockout in the epithelial layer of the intestinal mucosa. It resulted in an increase of NF-κB 
signaling which affects the permeability of tight junctions [42]. Delayed mucosal wound healing and 
the loss of intestinal barrier function resulted. This mechanism might also affect HCT116 cells upon 
shRNA  administration.  The  induction  of  NF-κB  could  increase  tight  junction  permeability  and  a 
disintegration of the cell mono-layer. 
2.2. Identification of a Stat5 Specific Peptide Ligand 
Peptide  aptamer  (PA)  constructs  are  fusion  proteins  composed  of  a  short  target  specific  PA 
sequence of 10 to 20 amino acids, integrated and presented in a constrained conformation on the 
surface  of  a  stable  scaffold  protein.  Compared  to  other  combinatorial  proteins  with  therapeutic Pharmaceuticals 2013, 6  967 
 
 
properties like antibodies or scFv-fragments, they possess several advantageous characteristics. PA are 
small  in  size,  of  simple  design  and  do  not  contain  disulfide  bridges.  They  can  be  used  against 
intracellular target structures [43,44]. The yeast-two-hybrid system (Y2H) has been established as a 
suitable  method  to  identify  PA  sequences  able  to  bind to  defined  protein target  domains  [43,45].  
This system allows the detection of protein interactions under intracellular conditions in eukaryotic 
yeast cells. In addition, effects of post-translational folding or secondary modifications, on the ligand 
protein  interactions can be studied. The Y2H system is based on the transcriptional regulation of 
reporter genes by the dimeric yeast transcription factor Gal4. Gal4 comprises a DNA-binding domain 
(DBD) and a transcriptional activation domain (AD) and is able to regulate gene expression when both 
domains  are  brought  into  close  proximity.  This  can  be  accomplished  by  non-covalent  protein 
interactions, mediated by proteins or protein-domains, expressed as fusion proteins with the Gal4-DBD 
or Gal4-AD, respectively. Reporter genes with designed, varying promoter strength, can be used to 
identify protein interactions of different intensity. PA sequences, specific ligands for a pre-determined 
target domain, can be identified from peptide expression libraries of high complexity. For this purpose, 
the target protein sequence is fused to the Gal4-DBD, bait fusion protein. The peptides are expressed 
as fusion proteins with the Gal4-AD, prey fusion proteins (Figure 2a). We used the DNA-binding 
domain of the human Stat5a protein (Stat5-DBD) as bait (Figure 2b). The DBD of the human Stat5 
isoforms exhibit an amino acid sequence homology of 97%. An oligonucleotide library, encoding 
random  12mer  PA  sequences  and  including  all  amino  acids  was  synthesized.  The  library  has  a 
theoretical diversity of 3 ×  10
15 sequences and a stop codon likelihood of 3.1%. It was prepared for 
screening as previously described [46]. 
The peptides were introduced into the protruding, active site of the 12 kDa human thioredoxin 
protein (hTRX), which served as the PA displaying scaffold fused to the Gal4-AD (Figure 2b). The 
introduction into the active loop inactivates the enzymatic activity of hTRX. Five cysteine residues 
present in hTRX, two in the active site and three in the carboxyl terminal part, have been substituted 
by  glycines  and  serines.  This  generated  an  optimized  version  of  the  hTRX  scaffold  (hTRX
Δcys5), 
unable  to  form  macromolecular  aggregates  by  disulfide-interactions during  protein  expression  and 
purification. These modifications strongly favor the monomeric form of recombinant hTRX
Δcys5 under 
non reducing conditions [19]. 
About 1 ×  10
7 distinct constructs from the peptide expression library were transformed into yeast 
cells and screened as prey-constructs for their binding to the Stat5-DBD under conditions of increasing 
stringency. Seven yeast clones were isolated. One of them exhibited superior binding strength after  
re-validation. The affinity of its interaction with the DBD of Stat5 was comparable to the affinity 
observed for the interaction between p53 and the SV40 largeT antigen (Figure 2c) which was used as a 
control. The interaction was also confirmed by the measurement of β-galactosidase activity and the 
Miller units (MU) measured corroborated the intense protein interaction. The specificity of binding of 
this PA was verified by comparative interaction measurements with the DBD and SH2-domains of 
Stat3 and Stat5. Only very weak binding to the Stat3-DBD was observed. This reflects the fact that the 
sequence homology between the DBD of Stat3 and Stat5 is only 42%. 
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Figure 2. Identification of a 12mer peptide aptamer sequence (S5-DBD-PA) that specifically 
binds with high affinity to the DNA-binding domain (DBD) of Stat5. (a) Yeast-two-hybrid 
(Y2H) screening strategy for the isolation of PA sequences that interact with a functional 
domain of human Stat5. Y2H screens were performed with a yeast strain (KF1) containing 
four different Gal4-dependent reporter genes of different stringency. This included genes 
for the biosynthesis of histidine (His-3), adenine (Ade-2) and uracil (Ura-3) as well as the 
LacZ-reporter  gene  for  β-galactosidase  expression  and  activity  measurement.  The 
corresponding  expression  vectors  (bait  and  prey)  were  co-transformed  into  yeast  cells, 
which were plated and grown under highly stringent conditions on selective media lacking 
uracil,  for  identifying  the  strongest  PA  interactions.  The  clone  with  the  best  binding 
properties after revalidation was chosen for further analysis. (b) Schematic representation 
of the cloned bait and prey fusion proteins used for Y2H screening. The DBD of human 
Stat5A comprises amino acids 331 to 473, indicated in red in the crystallographic structure 
of a Stat-dimer bound to DNA [47]. This domain was fused to the Gal4 DNA-binding 
domain  (Gal4-DBD)  and  used  as  bait.  The  complex  12-mer PA library was expressed 
within  the  active  loop  of  the  modified  human  thioredoxin  scaffold  (hTRX
Δcys5, 
schematically  indicated  by  the  hTRX  crystal  structure),  which  was  fused  to  the  Gal4 
transcriptional  activation  domain  (Gal4-AD).  These  random  PA  sequences  presenting 
fusion proteins were used as prey constructs. (c) The specificity of binding of the identified 
aptamer  (S5-DBD-PA)  to  the  STAT5-DBD  was  verified  after  plasmid  sequencing  and 
retransformation  by  plating  the  yeast  cultures  in  1:10,  1:100  and  1:1,000  dilutions  on 
selective  media  lacking  leucine  (L)  and  tryptophan  (T),  which  synthesis  genes  were 
encoded by the corresponding bait and prey expression vectors, and additionally either 
histidine (H), adenine (A) or uracil (U). Weak interactions allow growth on -LTH, whereas 
growth on -LTU requires strong interactions. The interaction of p53 or lamin C with the 
SV40 Large T antigen served as positive and negative controls. The Gal4-AD (GAD) fused 
S5-DBD-PA  binding  properties  against  the  single  GAL4-DBD  (GBD)  and  other  fused 
domains of Stat3 and Stat5 (DBD- or SH2-domain) were additionally evaluated. Protein 
interactions were also quantified by measuring β-galactosidase activity. Results are shown 
as Miller-Units (n = 3; Ø ±  SD). 
(a) 
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The S5-DBD-PA (Stat5-DBD specific PA) was equipped with functional domains which optimize 
its recombinant expression, protein purification and delivery into target cells by protein transduction. 
hTRX
Δcys5-presented S5-DBD-PA was fused with a protein transduction domain (PTD), consisting of 
9-arginine residues (9-R), and with a histidine tag at the carboxyl terminus. A nuclear localization 
sequence, NLS, for enhanced nuclear translocation and a Flag epitope tag for the immunohistochemical 
detection upon protein transduction were added to the amino terminus (Figure 3a). This multifunctional 
framework protein construct has been successfully tested before with a PA of 23 amino acids in length 
(rS3-PA).  This  protein  is  able  to  specifically  interfere  with  the  function  of  Stat3.  It  binds  to  the 
dimerisation  and  transactivation  domains  of  Stat3.  Recombinant  rS3-PA  is  rapidly  taken  up  by 
cultured cells upon addition to the growth medium and intracellularly interacts with its target domain. 
It causes the inhibition of Stat3 activation and dimerisation and reduces the viability and the growth of 
Stat3-dependent tumor cells [48]. The binding of S5-DBD-PA to the Stat5-DBD is expected to block 
the function of Stat5 and elicit similar phenotypes as rS3-PA (Figure 3b). 
Figure 3. Domain structure of the S5-DBD-PA protein construct used for viral and protein 
transduction  experiments  and  a  model  for  its  inhibitory  function.  (a)  The  Stat5-DBD 
specific 12mer PA sequence (S5-DBD-PA) was introduced in the protruding active loop of 
the hTRX
Δcys5 protein, which serves as a scaffold for enhanced binding affinity and stability. 
A protein transduction domain (PTD) consisting of 9 arginines (9-R) is added for intracellular 
uptake. Additionally a C- terminal histidine tag (His) for purification, a NLS-domain for an 
enhanced nuclear import and a N-terminal Flag-tag (Flag) for proper detection were added. 
The complete S5-DBD-PA protein construct has a size of 21 kDa. As a negative control for 
further analysis the scaffold protein, containing an unspecific 9mer linker sequence instead 
of the PA sequence was used. This control protein was termed hTRX and has a size of  
20  kDa. (b)  Model  for inhibition of the Stat5-DNA-binding activity by the interacting 
peptide ligand S5-DBD-PA. The specific interaction of S5-DBD-PA with the Stat5-DBD 
prevents the binding of Stat5 and its DNA response element. It blocks essential regions for 
the recognition and binding to GAS DNA. 
 
(a) 
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(b) 
2.3. S5-DBD-PA Interferes with the DNA-Binding Activity of Stat5 
The PA within the construct S5-DBD-PA was identified on the basis of its affinity to the DBD of 
Stat5.  This  binding  interaction  initially  does  not  ascertain  that  S5-DBD-PA  functions  as  a  Stat5 
inhibitor. We carried out experiments which confirmed our expectations that S5-DBD-PA is not only a 
Stat5-DBD ligand, but also an inhibitor of Stat5 functions. For this purpose electrophoretic mobility 
shift experiments and promoter-reporter assays were conducted. We observed that S5-DBD-PA can 
cause the inhibition of Stat5 binding to its DNA response element in gelshift (EMSA) experiments and 
that it can inhibit a luciferase reporter construct in cells. Recombinant S5-DBD-PA was added to cell 
culture  media  or  S5-DBD-PA  was  expressed  after  lentiviral  transduction.  The  experiments  were 
carried in a HeLa cell line (B9-HeLa), which stably overexpresses Stat5 and the PrlR. The stimulation 
of these cells with Prl leads to the induction of Stat5 tyrosine phosphorylation mediated by PrlR and 
Jak2 (Figure 4a). In control experiments, a scaffold construct, hTRX, was used which expresses an 
irrelevant peptide sequence (Figure 3a). 
The application of recombinant S5-DBD-PA to the cell culture medium at concentrations of 1 and  
2 µM  resulted in the uptake of the protein into the cells and a dose-dependent reduction of Stat5 DNA 
binding  (Figure  4b,c).  The  recombinant  S5-DBD-PA  construct  also  caused  the  reduction  of  the 
expression of the Stat5-regulated luciferase reporter gene. EMSA experiments were also performed 
with  extracts  from  Prl  stimulated, non-transduced  B9-Hela  cells.  The  S5-DBD-PA  and  the  hTRX 
control proteins were added also to cell lysates in vitro before the EMSA were carried out, which led to 
similar effects. The infection of the cells with lentivirus and subsequent intracellular expression of the 
proteins emphasized the ability of S5-DBD-PA to suppress the complex formation between Stat5 and 
its DNA response element (Figure 4d). 
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Figure 4. Inhibition of Stat5 DNA-binding by S5-DBD-PA. (a) Extracts of modified HeLa 
cells (B9-HeLa) were used for measuring the Stat5 DNA-binding activity by gelshift and 
luciferase reporter assays. Tyrosine phosphorylated Stat5-dimers are rapidly induced in 
these cells by Prl stimulation due to a stable overexpression of Stat5 and the PrlR. (b) 
Evaluation of Stat5 DNA binding activity by electrophoretic mobility shift assay (EMSA). 
For assessing the therapeutic potential of S5-DBD-PA after being taken up by target cells, 
Stat5  inducible  B9-HeLa  cells  were  treated  with  recombinant  S5-DBD-PA  and  the  
non-specific  hTRX-scaffold  control  protein  for  4  h  in  the  indicated  concentrations 
(experiment  on  the  left).  Stat5  was  activated  subsequently  by  adding  100  ng/mL  Prl. 
Untransduced  membrane  bound  proteins  were  removed  by  acid-wash  prior  to  lysate 
preparation.  Three  µg   of  the  cell  lysates  were  mixed  with  P
32-labelled  double  strand 
oligonucleotides  representing  a  Stat5  response  element  of  the  β-casein  promoter.  The 
reaction was carried out at room temperature for 30 min in a binding buffer. Lysates of 
uninduced or/and untreated cells were used as control. To underline the Stat5 mediated 
DNA shift a control oligonucleotide and a Stat5 antibody (supershift) was added. Another 
experiment was done without preincubation of the cells with the recombinant constructs 
(experiment on the right). B9-HeLa cells were stimulated for 30 min with Prl directly and 
lysates  were  prepared.  10  µg   of  the  lysates  were  incubated  for  2  h  with  5  µg   of 
recombinant S5-DBD-PA or hTRX under shaking at room temperature. 3 µg  of the protein 
mixtures and 3 µg  of untreated B9-HeLa cell lysates (−/+ Prl) were used for the assay. (c) 
Measurement  of  Stat5-regulated  luciferase  expression  with  the  dual  luciferase  reporter 
assay.  B9-HeLa  cells  were  co-transfected  with  a  firefly  luciferase  Stat5-reporter  and  a 
renilla luciferase control reporter to improve the accuracy of the measurement. After 2 days 
cells were treated for 4 h either with S5-DBD-PA or the scaffold control construct (hTRX) 
in the indicated concentrations or with the same volume of solvent (dialysis buffer) or PBS. 
Stat5 was induced by adding 100 ng/mL  Prl and luciferase activity was detected after 
further 4 h. (n = 3; Ø ±  SD) Significantly reduced luciferase activities in comparison to 
PBS treated cells are indicated. ** p < 0.01 (1-way-ANOVA with Bonferroni correction) 
(d)  Stat5  DNA-binding  is  inhibited  by  intracellular  S5-DBD-PA  expression.  STAT5 
inducible  B9-HeLa  cells  were  transduced  with  the  pSiEW  lentiviral  vector  expressing 
either  S5-DBD-PA,  hTRX  or  the  empty  vector.  10  days  after  infection  STAT5  was 
activated by adding 100 ng/mL Prl and cellular lysates were taken. 4µ g of the cell lysates 
were analyzed by EMSA as described before. As controls a Stat5 supershift and lysates of 
untreated B9-HeLa cells (−/+ Prl) were used. 
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2.4. The Binding of S5-DBD-PA to the DBD of Stat5 Prevents the Nuclear Translocation of Stat5 upon 
Prolactin Stimulation in T-47D Cells 
We  infected  T-47D  cells  with  a  lentiviral  gene  expression  vector  encoding  S5-DBD-PA  and 
analyzed the intracellular location of endogenously expressed S5-DBD-PA by immune fluorescence 
and  confocal  microscopy.  T-47D  cells  have  been  derived  from  an  invasive  breast  cancer  and  are 
characterized by PrlR expression. Stat5 can be activated in these cells by Prl stimulation (Figure 5a). 
We compared the intracellular location of S5-DBD-PA in Prl treated and control T-47D cells (Figure 5b). 
In unstimulated T-47D cells, S5-DBD-PA is mainly present in the nucleus. It is possibly associated 
with unphosphorylated Stat5. Upon treatment of the cells for 30 minutes with Prl, Stat5 was activated 
and the accumulation of S5-DBD-PA in the cytoplasm was observed. The expression of the hTRX 
protein was followed in control cells. This protein is equally distributed in cytoplasmic and nuclear cell 
compartments,  independent  of  a  Prl-stimulation.  Activated  Stat5  enters  the  nucleus  by  nuclear 
translocation, mediated by the interaction of importin-α complexes with a NLS-sequence within the 
DBD of Stat proteins. They become exposed upon dimer formation [4,49]. In hTRX expressing T-47D 
cells active Stat5-dimers are found in the cytoplasm and in the nucleus 30 minutes after Prl induction. 
In S5-DBD-PA expressing cells nearly all tyrosine phosphorylated Stat5 was found in the cytoplasm 
and co-localized with S5-DBD-PA.  We conclude that the binding of S5-DBD-PA to the DBD of 
activated Stat5-dimers prevents their nuclear translocation, a process which contributes to the functional 
Stat5 inhibition. 
Figure  5.  S5-DBD-PA  interferes  with  the  nuclear  translocation  of  Stat5  upon  
prolactin induction. (a) Stat5-activation in T-47D breast cancer cells stimulated with Prl. 
(b)  Immunofluorescent  images  of  lentiviral  transduced  T-47D  cells  either  expressing  
S5-DBD-PA  or  hTRX  were  taken  7  days  after  infection  by  confocal  laser  scanning 
microscopy in the absence or presence of Prl. Cells were stained with a Flag-tag antibody, 
marked with a Alexa 546 conjugated secondary antibody, and a Alexa 647 conjugated 
antibody  recognizing  tyrosine  phosphorylated  Stat5a  and  Stat5b.  Nuclear  staining  was 
performed with DAPI and fluorescence marker (eGFP) expression of the SiEW-lentiviral 
transfer vector was monitored. 
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2.5. S5-DBD-PA Suppresses the Viability of Tumor Cells 
The inhibition of Stat5 function in tumor cells has consequences for cell viability and cell growth. 
We carried out experiments to evaluate the potential effects of S5-DBD-PA on these parameters. We 
infected  A431,  PC-3, T-47D and HCT116 cells with lentiviral vectors encoding S5-DBD-PA, the 
hTRX non-specific scaffold control or an empty vector. Vector induced expression of S5-DBD-PA 
resulted in significant reductions of growth and viability during the first three weeks after infection 
(Figure 6). HCT116 cells, cells with very low Stat5 expression, were only slightly affected. These 
results confirm the observations made by downregulation of Stat5 expression through RNAi, described 
above. A431, PC-3 and T-47D cells are most strongly affected. S5-DBD-PA is able to suppress Stat5 
function and cause the reduction of cell growth. The growth inhibition induced by a Stat5 mRNA 
downregulation,  however,  was  more  pronounced.  It  is  possible  that  the  shRNA  mediated 
downregulation of Stat5 expression affects more of the Stat5 functions, canonical and non-canonical 
ones, than the complex formation with S5-DBD-PA. In A431 and PC-3 cells it is reasonable to assign 
the reduction in cellular viability to the loss of the Stat5 transactivation function due to S5-DBD-PA 
binding.  This  confirms  previously  published  results.  Prostate  cancer  cell  survival  and  growth, 
dependent upon Stat5-regulated gene expression, has been described [24,31]. Not entirely expected, 
however, was the observation that unstimulated T-47D cells were affected by the S5-DBD-PA ligand. 
These cells exhibit no Stat5 activation in the absence of cytokine treatment, i.e., their survival is not 
dependent  upon  the  expression  of  Stat5  target  genes.  Immunofluorescence  analyses  revealed  the Pharmaceuticals 2013, 6  976 
 
 
presence of S5-DBD-PA in the nucleus of unstimulated T-47D cells (Figure 5b). It is possible that  
S5-DBD-PA is associated with non-phosphorylated Stat5 in the nucleus. This association might inhibit 
the function of Stat5 as a cofactor of transcription. Such a function has been suggested in support of 
glucocorticoid receptor mediated transcription in mammary cells or hepatocytes [50,51]. 
Figure 6. S5-DBD-PA suppresses the viability and the growth of tumor cells. (a) A431 
epidermal, PC-3 prostate and HCT116 colorectal carcinoma cell lines were infected with 
SiEW-lentiviral vectors encoding either S5-DBD-PA, hTRX or the empty vector. Over a 
period of 20 days cell viability and concomitant growth was monitored by XTT assay. 
Results are shown as the percentage of viable cells compared to the mock-treated control. 
Stat5 and transgene expression was verified by western blot 7 days after infection using 
antibodies recognizing either total or tyrosine phosphorylated Stat5 protein and a flag tag 
antibody. (b) The same experiments were done with unstimulated T-47D breast cancer 
cells.  Protein  expression  was  analyzed  after  7  days  with  and  without  30  min  Prl 
stimulation. (n = 3; Ø ±  SD). Significantly reduced XTT-values in comparison to empty 
vector expressing cells are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001 (2-way-ANOVA 
with Bonferroni correction). 
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(b) 
Figure 7. Suppression of tumor cell growth and viability by transduction of recombinant 
S5-DBD-PA.  S5-DBD-PA  was  transduced  into  the  four  tumor  cell  lines  A431,  PC-3,  
T-47D and HCT116 by adding 0.5, 1, 1.5 µM  of recombinant S5-DBD-PA to the culture 
medium. The treatment with the scaffold control protein (hTRX) in a 1.5 µM  concentration 
as well as with the same volume of protein-solvent (dialysis buffer) and PBS served as 
negative  controls.  Medium  and  peptides  were  replaced  daily  and  cell  viability  and 
concomitant growth was determined by XTT assay. Results are shown as the percentage of 
viable  cells  compared  to  the  PBS  control.  (n  =  3;  Ø  ±   SD)  Significantly  reduced  
XTT-values  in  comparison  to  protein-solvent  treated  cells  are  indicated.  *  p  <  0.05,  
** p < 0.01, *** p < 0.001 (2-way-ANOVA with Bonferroni correction). 
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Non-canonical functions of Stat5 have to be taken into consideration when Stat5 antagonists are 
being evaluated as potential cancer therapeutics and individual compounds might have differential 
effects. Tyrosine phosphorylated Stat5 was diminished in the presence of S5-DBD-PA in PC-3 cells 
and, to lesser extent, also in A431 and Prl stimulated T-47D cells (Figure 6). We do not a priori expect 
that the binding of S5-DBD-PA to the Stat5-DBD should interfere with the phosphorylation of Stat5. 
This  is  a  consequence  we  can  attribute  to  the  Stat3-specific  inhibitor  rS3-PA  which  blocks  the 
phosphorylation site [48]. The reduction of P-Stat5 could be due to enhanced proteasomal degradation 
of activated Stat5-dimers associated with S5-DBD-PA making S5-DBD-PA a potent inhibitor of Stat5 
and Stat5 dependent tumor cells (Figure 7). 
3. Experimental 
3.1. Cell Lines and Culture Conditions 
The human epidermal carcinoma cell lines A431 (ATCC: CRL-1555) and B9-HeLa (ATCC HeLa: 
CCL-2) as well as the human prostate cancer cell line PC-3 (ATCC: CRL-1435) and the lentiviral 
producer cell line 293T (HEK-293T, ATCC: CRL-11268) were grown in DMEM medium. Human 
HCT116 colorectal cancer cells (ATCC: CCL-247) and T-47D breast cancer cells (ATCC: HTB-133) 
were cultured in RPMI 1640 medium. Media were obtained from Gibco
® Life Technolgies (Carlsbad, 
CA,  USA)  or  Lonza  Group  (Basel,  Switzerland)  and  supplemented  with  10%  FCS,  L-glutamine  
(2 mM) and penicillin/streptomycin (100 U/mL; 100 µ g/mL). All cells were passaged regularly every 
3–4 days and were grown at 37 ° C, 5% CO2 and 98% humidity. The modified HeLa cell line B9 was 
generated before in the lab and is characterized by a stable overexpression of Stat5 and PrlR. For Prl 
stimulation experiments, 100 ng/mL recombinant human Prl was added to the cell culture medium of 
B9-HeLa and T-47D cells for 15–30 min. 
3.2. Reagents 
Anti-Flag  (M2,  clone  2)  and  -Tubulin  (T  0198,  clone  D66)  antibodies  were  obtained  from  
Sigma-Aldrich (St. Louis, MO, USA). STAT3 (C-20, sc-482) and STAT5 (C-17, sc-835) antibodies 
were from Santa Cruz Biotechnology (Dallas, TX, USA). P-STAT5 (C11C5, *9359: Tyr694 Stat5a; Pharmaceuticals 2013, 6  979 
 
 
Tyr699  Stat5b)  and  P-STAT5-Alexa  Fluor
®647  (C71E5,  *9365:  Tyr694  Stat5a;  Tyr699  Stat5b) 
antibodies were purchased from Cell Signaling (Cambridge, UK). XTT Cell Proliferation Kit II was 
obtained from Roche Diagnostics (Rotkreuz, Switzerland). Lipofectamine
® LTX & Plus Reagent was 
from  Life  Technolgies  (Invitrogen,  Carlsbad,  CA,  USA).  Recombinant  human  prolactin  (Prl)  was 
purchased from Sigma-Aldrich. Dual-Luciferase
® Reporter (DLR™) Assay System was obtained from 
Promega (Fitchburg, WI, USA). 
3.3. Plasmid Construction 
For interaction assays in the yeast two-hybrid system, pGAD-T7 (prey expression) and pGBK-T7 
(bait expression) vectors (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) were used. 
For bait expression the DNA-binding domain (DBD) of the human Stat5a protein (amino acids 331–473) 
was cloned in frame with the Gal4-DNA binding domain into the MCS of the pGBK-T7 vector. The 
hTRXΔcys5 scaffold was fused with the Gal4-AD as previously described [19]. The 12mer PA library 
was  synthesized  by  Eurofins  MWG  Operon  as  random  oligonucleotides,  using  a  NNK-codon 
definition (N = A,T,C,G; K = T,G), and with hairpin structure for complementary strand elongation, as 
described before [46]. By using glycine and proline encoding 5′-ApaI and 3′-SmaI restriction sites the 
double strand oligonucleotide-library was cloned into the active site of hTRXΔcys5 in mono-directional 
NNK order. 
For  bacterial  expression,  the  pFlag-2  vector  (Sigma-Aldrich)  was  used.  In  order  to  create  the 
complete  S5-DBD-PA  peptide  aptamer  construct,  applicable  for  protein  transduction,  purification, 
nuclear  translocation  and  proper  detection,  the  hTRXΔcys5  scaffold  with  the  Stat5-DBD  specific 
12mer  PA  sequence  was  cloned  together  with  a  NLS-sequence,  the9-R  PTD  and  the  6xHis  tag,  
C-terminal of the Flag tag as previously described [48]. 
For the stable expression of human Stat5a and Stat5b directed shRNA the lentiviral pLeGO-G 
vector (Lentiviral Gene Ontology Vectors: www.lentigo-vectors.de) was used. The validated shRNAs 
were obtained from Sigma-Aldrich [MISSION
® shRNA] introduced into the lentiviral pLKO.1-puro 
vector  with  puromycin  selectable  marker.  For  the  documentation  of  the  transduced  cells  by 
fluorescence  microscopy  and  for  the  determination  of  precise  viral  titers  by  FACS,  the  shRNA 
sequences were cloned along with the pLKO.1-puro U6-promoter in the pLeGO-G vector with eGFP 
selectable marker. Thereby the U6-promoter of the pLeGO-G vector was replaced. The sequences of 
the processed siRNA antisense strands were for human Stat5a (TRCN0000019308): 5′ ATCCTGAT 
CGAGTACATGGTC 3′, and for human Stat5b (TRCN0000019356): 5′ ATCTGGCTTGTTAATGA 
GTAG  3′.  A  non  mammalian  shRNA  from  Sigma-Aldrich  [MISSION
®  shRNA],  (*SHC002, 
TRC1/1.5): 5′ TTGGTGCTCTTCATCTTGTTG 3′, was cloned from pLKO.1-puro into the lentiviral 
pLeGO-C vector with mCherry red fluorescent marker. For the stable expression of S5-DBD-PA and 
the hTRX non-specific scaffold control construct in the target cells, the complete Flag-NLS-hTRX-9R-
6xHis cassette was cloned into the lentiviral pSiEW vector via a single SacII-restriction site. Here 
transgene expression was driven by a spleen focus-forming virus (SFFV) promoter, which also drives 
the expression of eGFP through an internal ribosome entry site (IRES). All used lentiviral transfer 
plasmids had an HIV-1 derived vector backbone with SIN-configuration (self-inactivating) for safety, Pharmaceuticals 2013, 6  980 
 
 
replication incompetent transgene expression, due to a deletion of promoter and enhancer sequences in 
the 3′-LTR. 
3.4. Lentiviral Vector Production and Target Cell Infection 
For the infection of the target cells, VSV-G pseudotyped lentiviral SIN-vectors were produced by 
calcium phosphate coupled transfection of the pCMVΔR8.91 plasmid, encoding HIV-1 derived gag, 
pol, rev and tat genes, the VSV-G envelope encoding pMD2.VSV-G vector and the respective transfer 
plasmid  into  the  293T  packaging  cell  line,  as  described  before  [52].  Lentiviral  particle  enriched 
supernatants were collected 48, 72, and 96 h after transfection, concentrated by ultracentrifugation and 
stored in aliquots at −80 ° C. The viral titer was determined by transducing 293T cells with serially 
diluted virus, followed by a FACS analysis after 2 days. For transduction experiments, the target cells 
were infected with an MOI = 20 (multiplicity of infection: amount of viral particles used for infection 
of one target cell). After 24 h the target cells got fresh media after they were washed with PBS. 
3.5. Yeast-Two-Hybrid Screen 
The PA screening was done in the yeast strain KF1 (MAT_ trp1–901 leu2–3, 112 his 3–200 gal4D 
gal80D LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ SPAL10-URA3) [53], which contains three 
Gal4-regulated  reporter  genes  for  biosynthesis  of  histidine,  adenine  and  uracil  and  an  additional  
LacZ-reporter gene for β-galactosidase activity measurements. Depending on the promoter strength, 
these reporter genes allowed a detection of protein interactions with different affinities. As bait, the 
DNA-binding domain (DBD) of the human Stat5a protein was fused with the Gal4-DNA binding 
domain, using the pGBK-T7vector as described above [Matchmaker
TM GAL4 Two-Hybrid System 3 
from  Clontech-Takara  Bio  Europe].  The  prey  constructs  were  designed  as  random  12mer  PA 
expression library with a theoretical diversity of 3 ×  10
15 possible sequences, by using the vector 
pGAD-T7 [Matchmaker
TM GAL4 Two-Hybrid System 3 from Clontech] as template. Therefore the 
optimized human thioredoxin scaffold (hTRX
Δcys5) first was cloned in frame with the Gal4-Activation 
domain, before the synthetic oligonucleotide library was inserted into the active site of hTRX
Δcys5 (for 
cloning details see plasmid construction above). Cloned library vectors (prey) were amplified in E. coli, 
from  which  approximately  1  ×   10
7  different  vectors  were  transformed  into  yeast  and  screened. 
KF1transformants expressing the bait constructs and the prey-library were selected for growth under 
high stringent conditions in the absence of uracil. Growing KF1-colonies were collected for plasmid 
extraction and sequence analysis. After that, false positives were excluded and prey-plasmids with 
correct open reading frame of Gal4-AD, hTRX
Δcys5 and 12mer PA sequence were retransformed and 
the interaction was verified by yeast-two-hybrid serial dilution and β-galactosidase assay. 
3.6. Recombinant Protein Expression, Protein Purification and Transduction 
Recombinant  expression  and  subsequent  purification  of  S5-DBD-PA  and  hTRX  by  Ni
2+-chelat 
affinity  chromatography,  using  a  FPLC  system,  was  done  as  described  earlier  [19].  For  protein 
transduction of eukaryotic target cells, the recombinant proteins were added to cell culture media in 
concentrations indicated in the figure legends. To remove untransduced membrane bound proteins, the Pharmaceuticals 2013, 6  981 
 
 
cells were washed twice with PBS and once with PBS containing 0.2 M acetic acid prior to cell lysis 
(acid wash). 
3.7. Electrophoretic Mobility Shift assay (EMSA) 
Whole-cell extracts of Prl stimulated B9-HeLa cells, treated with S5-DBD-PA, hTRX or control as 
indicated in the figure legends, were prepared with a lysis buffer [50 mM Tris (pH 7.4), 100 mM NaCl, 
1 mM DTT, 1 mM EDTA, 0.1% Triton X-100, 10% glycerol, phosphatase and protease inhibitors 
were added freshly] for 30 min on ice. Equal amounts of each extract (3–4 μg total protein) were 
incubated with radioactive marked oligonucleotides, representing a Stat5-specific response element of 
the β-casein promoter (5′ TTCTTGGAATTGAAGGGACTT 3′), for 30 min at room temperature in a 
binding buffer (20 mM HEPES, 1 mM EDTA, 20 mM KCl, 1 mM DTT, 2 mM MgCl2, 100 µ g/µ L 
BSA). Samples were loaded on a native 4% TBE-polyacrylamide gel and Stat5-DNA complexes were 
separated from unbound oligonucleotides by electrophoresis. For the verification of the Stat5-DNA 
complex after electrophoresis a supershift was performed by preincubation of a lysate sample for  
20  min  with  an  anti-Stat5  antibody  (C17;  Santa  Cruz  Biotechnology)  at  room  temperature. 
Furthermore a scrambled oligonucleotide and lysates of unstimulated B9-HeLa cells served as control. 
3.8. Transient Transfection and Dual-Luciferase Reporter Assay 
For the measurement of Stat5-regulated luciferase expression prolactin inducible B9-HeLa cells 
were used and seeded at 0.8 ×  10
5 cells per 24-well. After 24 h the cells were cotransfected with  
0.5–1  µg   of  a  firefly-luciferase  reporter  plasmid  (pStat5[RE]2-TA-Luc),  where  firefly  luciferase 
expression  is  regulated  by  Stat5  consensus  response  elements  of  the  β-casein  promoter  (5′ 
TTCTTGGAATTGAAGGGACTT  3′),  and  25  ng  of  a  constitutively  renilla-luciferase  expressing 
control reporter plasmid (pGL4.74[hRluc/TK]). Transient transfection was done with Lipofectamine
® 
LTX (Life Technolgies, Invitrogen) according to the manufacturer’s protocol. After further 24 h the 
cells  were  incubated  with  recombinant  S5-DBD-PA,  hTRX  and  control  for  4  h,  using  2%  FCS 
starvation medium, before Prl stimulation. After another 4 h cells were lysed, detection reagents added 
and samples measured in a luminometer according to manufacturer’s protocol, using the Dual-Luciferase
® 
Reporter (DLR™) Assay System from Promega. Normalization of the experimental reporter activity 
against the constitutively expressed renilla-luciferase reference reduced the experimental variability 
caused by differences in cell viability or transfection efficiency. 
3.9. Western Blot Analysis 
Cells were washed twice with ice-cold PBS and solubilized in immunoprecipitation assay lysis 
buffer  [50  mmol/L  Tris  (pH  7.4),  150  mmol/L  NaCl,  1%  NP40,  0.5%  sodium  desoxycholate,  
1 mmol/L EDTA, protease inhibitiors], and incubated on ice for 20 min. Lysates were clarified by 
centrifugation at 16,000 ×  g for 10 min. For SDS-PAGE, 20–30 µg  of each protein sample were 
loaded. Gels were blotted onto nitrocellulose membranes, which were probed with specific antibodies 
as  indicated  in  the  figure  legends.  Proteins  were  visualized  with  peroxidase-coupled  secondary 
antibodies with the chemiluminescence system (GE-Healthcare, Chalfont St Giles, UK). Pharmaceuticals 2013, 6  982 
 
 
 
3.10. Immunofluorescence Staining 
Lentiviral transduced and S5-DBD-PA and hTRX expressing T-47D cells were grown on coverslips 
and stimulated for 30 min with Prl. Cells were fixed and permeabilized with the Cytofix/Cytoperm
TM 
permeabilization  and  wash  buffer  system  from  BD-Becton  Dickinson (Franklin  Lakes,  NJ,  USA).  
For the detection of flag tagged proteins and tyrosine phosphorylated Stat5 the cells were incubated 
with  anti-Flag  M2  primary  antibody  (Sigma-Aldrich)  and  an  Alexa  Fluor
®647  conjugated  
P-STAT5(Tyr)-antibody (Cell signaling) for 30 min at room temperature with Cytofix/Cytopermwash 
buffer (antibody amounts were used according to the manufacturer). After the washing steps, an Alexa 
Fluor
®546  conjugated  anti-mouse  secondary  antibody  (Life  Technologies,  Invitrogen)  was  added 
together with nuclei staining DAPI (1 mg/mL). Cells were incubated for another 30 min. Finally, cells 
were prepared for confocal laser scanning microscopy by adding mounting medium (ProLong
® Gold 
Antifade; Invitrogen) and analyzed. 
3.11. XTT - Proliferation and Viability Assay 
XTT assays were done to study changes in cell viability and proliferation upon Stat5 inhibition. 
With lentiviral transduced cells, the experiment was started 24 h after infection by seeding 2,000 cells 
with 100 µ L medium in 96 wells. At intervals of 3 to 4 days the cells were analyzed over a period of 
20 days, whereas medium was exchanged regularly. S5-DBD-PA protein transduction experiments 
were done over 5 days. After seeding again 2.000 cells into 96 wells the experiment was started at the 
following day. Daily fresh medium was added to the cells, containing either S5-DBD-PA (0.5; 1;  
1.5  µ M),  hTRX  (1.5  µ M)  or  the  same  volume  of  protein  solvent  (dialysis  buffer)  or  PBS.  The 
treatment  and  XTT-measurement  was  done  daily  in  this  experiment.  XTT  values  were  measured, 
according to the manufacturer’s protocol (Roche Diagnostics, Rotkreuz, Switzerland), which assess 
cell viability via bioreduction of a tetrazolium compound. Spectrophotometric quantification was done 
at 490 nm on a plate reader. 
4. Conclusions 
Our  experiments  provide  evidence  that  Stat5  is  a  promising  drug  target  in  cancer  therapy  and 
validate peptide ligands as inhibitors of specialized functions of multi-domain proteins. PA can be 
directed against functional domains of Stat proteins and their complex formation with their intact 
target can cause the inhibition of phosphorylation, dimerization or DNA binding. These insights can be 
extrapolated and used in the context of other non-conventional drug targets [54]. Stat5 is expressed in 
nearly all tissues of mammalian organisms. Stat5 regulated functions comprise the canonical regulation 
of  gene  transactivation  in  the  nucleus  as  well  as  non-canonical  functions  in  the  cytoplasm  and 
mitochondria of cells. The RNAi experiments in this study emphasize the importance of the diversity 
of Stat5 functions for cellular fates. Downregulation of Stat5 indicates an addiction to Stat5 protein 
expression in tumor cells in culture. Several recent reports indicate that Stat5 inhibition could become 
beneficial for patients with varying indications. The JAK1/2 inhibitor ruxolitinib has been used to 
prevent Stat5 activation in patients with myeloproliferative neoplasms (MPN). It blocked cytokine and Pharmaceuticals 2013, 6  983 
 
 
inflammatory  responses  and  caused  the  cell  cycle  arrest  of  MPN  cells,  the  cells  did  not  show  a 
reduction  in  Stat5  expression  or  the  induction  of  apoptosis.  The  systemic  interference  with  Stat5 
activation, however, might also be associated with side effects. Persistent ruxolitinib treatment caused 
viral infections due to detrimental effects on immune cell functions [55]. Stat5 ligands which only 
affect discreet functional domains of Stat5 might become useful to avoid unwanted side effects. The 
inhibition of particular, tumor cell specific functions of Stat5 would be desirable and peptide based 
ligands could function as lead compounds [56,57]. Advances in delivery methods could result in the 
improvement of drug like properties of these peptides. Alternatively, their introduction into appropriate 
screening systems might yield low molecular weight compounds with similar functional properties [54]. 
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